lapatinib has been researched along with zm 252868 in 1 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (zm 252868) | Trials (zm 252868) | Recent Studies (post-2010) (zm 252868) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 14 | 0 | 1 |
| Protein | Taxonomy | lapatinib (IC50) | zm 252868 (IC50) |
|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | 0.0714 | |
| Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | 0.143 | |
| Receptor tyrosine-protein kinase erbB-4 | Homo sapiens (human) | 0.049 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Almenara, JA; Campbell, DJ; Dewitt, JL; Oyesanya, RA; Sirica, AE; Zhang, Z | 1 |
1 other study(ies) available for lapatinib and zm 252868
| Article | Year |
|---|---|
Preclinical assessment of simultaneous targeting of epidermal growth factor receptor (ErbB1) and ErbB2 as a strategy for cholangiocarcinoma therapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cell Proliferation; Cholangiocarcinoma; Disease Models, Animal; ErbB Receptors; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Rats; Receptor, ErbB-2; Signal Transduction; Tyrphostins | 2010 |